PubMed record Xiao B, Xu Z, Viennois E, et al
With respect to diagnosis of adult GHD of classical etiology, guidelines state that adult patients with structural hypothalamic/pituitary disease, surgery or irradiation in these areas, head trauma, or evidence of other pituitary hormone deficiencies are considered appropriate for acquired GHD and that idiopathic GHD as which occurs during aging requires stringent criteria to make the diagnosis
Telomerase activation is its signature mechanism: Epitalon can activate telomerase and lengthen telomeres in human cells, extending their replicative lifespan beyond the Hayflick limit, while preserving youthful morphology and function, though this benefit must be weighed against potential cancer risks
Always handle and dispose of research materials in accordance with institutional biosafety and laboratory safety requirements
GH secretagogue comparison Property Class CJC-1295 No DAC GHRH analog CJC-1295 with DAC GHRH analog (binds albumin) Sermorelin GHRH analog Ipamorelin GHRP (ghrelin mimetic) Property Half-life CJC-1295 No DAC ~30 minutes CJC-1295 with DAC 68 days Sermorelin 1020 minutes Ipamorelin ~2 hours Property Dosing frequency CJC-1295 No DAC 13x daily CJC-1295 with DAC 12x weekly Sermorelin 12x daily Ipamorelin 13x daily Property Common dose range CJC-1295 No DAC 100300 mcg per injection CJC-1295 with DAC 1,0002,000 mcg per week Sermorelin 100500 mcg per injection Ipamorelin 100300 mcg per injection Property GH release shape CJC-1295 No DAC Pulsatile, physiological CJC-1295 with DAC Sustained elevation Sermorelin Pulsatile Ipamorelin Brief, selective pulse Property FDA status CJC-1295 No DAC Not approved CJC-1295 with DAC Not approved Sermorelin Previously approved
Back DiMarchi, Richard, email to Lara Marks, 8 April 2025